OTCMKTS:SKBI - Skystar Bio-Pharmaceutical Stock Price, Price Target & More

$0.0001 -0.01 (-98.89 %)
(As of 04/23/2018 03:13 PM ET)
Previous Close$0.0090
Today's Range$0.0001 - $0.0001
52-Week Range$0.0001 - $0.07
Volume15,900 shs
Average Volume5,823 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Skystar Bio-Pharmaceutical (OTCMKTS:SKBI)

Skystar Bio-Pharmaceutical Co., Ltd. is a manufacturer and distributor of veterinary medicines and healthcare products in China. The Company develops, manufactures, packages and distributes vaccines; Western medicines, Traditional Chinese Medicine (TCM); topicals, supplements, probiotics, and diagnostic kits and animal, animal nutrition supplements for poultry, livestock, marine aquaculture and domesticated pets within China. The Company operates four product lines: Probiotics, Veterinary Medicine, Veterinary Vaccines and Feed Additives. The Company provides a range of veterinary products serving regional micro-farms offering, such as Veterinary vaccines, including aquaculture, Veterinary medicines, Pro-biotic microorganisms and Animal feed additives. The Company's Veterinary drug products include Ivermectin Premix, Feizhu San, Tilmicosin Premix, Stimulated egg powder, Wulingsan, Yimu Shenghua San, Qingwen Baidu San and Spectinomycin Hydrochloride Injection.

Receive SKBI News and Ratings via Email

Sign-up to receive the latest news and ratings for SKBI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares8,700,000

How to Become a New Pot Stock Millionaire

Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) Frequently Asked Questions

What is Skystar Bio-Pharmaceutical's stock symbol?

Skystar Bio-Pharmaceutical trades on the OTCMKTS under the ticker symbol "SKBI."

Who are some of Skystar Bio-Pharmaceutical's key competitors?

Who are Skystar Bio-Pharmaceutical's key executives?

Skystar Bio-Pharmaceutical's management team includes the folowing people:
  • Weibing Lu, Chairman of the Board, Chief Executive Officer (Age 51)
  • Bing Mei, Chief Financial Officer (Age 51)
  • Wei Wen, Secretary, Director (Age 46)
  • R. Scott Cramer, Director (Age 50)
  • Mark D. Chen, Independent Director (Age 47)
  • Qiang Fan, Independent Director (Age 58)
  • Chengtun Qu, Independent Director (Age 48)
  • Weirong Shen, Independent Director (Age 48)

Has Skystar Bio-Pharmaceutical been receiving favorable news coverage?

Media headlines about SKBI stock have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Skystar Bio-Pharmaceutical earned a coverage optimism score of 0.16 on Accern's scale. They also assigned news articles about the healthcare company an impact score of 44.54 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Skystar Bio-Pharmaceutical?

Shares of SKBI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Skystar Bio-Pharmaceutical's stock price today?

One share of SKBI stock can currently be purchased for approximately $0.0001.

How can I contact Skystar Bio-Pharmaceutical?

Skystar Bio-Pharmaceutical's mailing address is RM 10601 JIEZUO PLAZA NO. 4 FENGHUI ROAD SOUTH, XIAN F4, . The healthcare company can be reached via phone at 86-29-8819-3188 or via email at [email protected]

MarketBeat Community Rating for Skystar Bio-Pharmaceutical (SKBI)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  41 (Vote Underperform)
Total Votes:  75
MarketBeat's community ratings are surveys of what our community members think about Skystar Bio-Pharmaceutical and other stocks. Vote "Outperform" if you believe SKBI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SKBI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 4/23/2016 forward)


Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) Earnings History and Estimates Chart

Earnings by Quarter for Skystar Bio-Pharmaceutical (OTCMKTS:SKBI)

Skystar Bio-Pharmaceutical (OTCMKTS SKBI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2014Q3 2014$0.57$18.35 millionViewN/AView Earnings Details
8/14/2014Q2 2014$0.36$14.24 millionViewN/AView Earnings Details
5/15/2014Q413$0.13$5.53 million$6.83 millionViewN/AView Earnings Details
3/31/2014Q4 2013$0.29$9.63 millionViewN/AView Earnings Details
11/15/2013Q313$0.49$8.93 million$15.99 millionViewN/AView Earnings Details
8/15/2013Q1 2013$0.49$8.90 million$11.30 millionViewN/AView Earnings Details
5/16/2013Q113$0.09$7.93 million$5.53 millionViewN/AView Earnings Details
4/2/2013Q4 2012($0.02)ViewN/AView Earnings Details
11/15/2012Q312$0.36$20.90 million$8.90 millionViewN/AView Earnings Details
8/14/2012Q2 2012$0.23ViewN/AView Earnings Details
5/16/2012Q1 2012$0.26ViewN/AView Earnings Details
4/2/2012Q4 2011$0.34ViewN/AView Earnings Details
11/14/2011Q3 2011$1.08ViewN/AView Earnings Details
8/22/2011Q2 2011$0.16ViewN/AView Earnings Details
5/23/2011Q1 2011$0.19$0.20ViewN/AView Earnings Details
4/12/2011Q4 2010$0.55ViewN/AView Earnings Details
11/16/2010Q3 2010$0.47$0.93ViewN/AView Earnings Details
8/17/2010Q2 2010$0.32$0.36ViewN/AView Earnings Details
5/18/2010Q1 2010$0.14$0.20ViewN/AView Earnings Details
3/31/2010Q4 2009$0.41$0.37ViewN/AView Earnings Details
11/16/2009Q3 2009$0.42$0.38ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Skystar Bio-Pharmaceutical (OTCMKTS SKBI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.80%
Insider Trading History for Skystar Bio-Pharmaceutical (OTCMKTS:SKBI)

Skystar Bio-Pharmaceutical (OTCMKTS SKBI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/26/2015John M GregoryMajor ShareholderBuy63,900$2.91$185,949.00View SEC Filing  
5/6/2015John M GregoryMajor ShareholderBuy50,000$3.47$173,500.00View SEC Filing  
4/16/2015John M GregoryMajor ShareholderBuy35,000$3.82$133,700.00View SEC Filing  
2/2/2015John M GregoryMajor ShareholderBuy38,730$4.21$163,053.30View SEC Filing  
12/23/2014John M GregoryMajor ShareholderBuy70,800$4.28$303,024.00View SEC Filing  
12/10/2014John M GregoryMajor ShareholderBuy103,016$4.56$469,752.96View SEC Filing  
(Data available from 1/1/2013 forward)


Skystar Bio-Pharmaceutical (OTCMKTS SKBI) News Headlines

No headlines for this company have been tracked by MarketBeat.com

SEC Filings

Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) Income Statement, Balance Sheet and Cash Flow Statement


Skystar Bio-Pharmaceutical (OTCMKTS SKBI) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.